The Journal of Urology · 1989 · 34 citations · 15 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyNeoplasiaInterferon-based TherapyKidney CancerRenal Cell CarcinomaRenal NeoplasmsAntitumor Interferon ResponsesInterferon Alfa TherapyInterferon Alpha-2b TherapyPhase Ii InvestigationStudy Phase
A total of 66 patients with advanced renal cell cancer received a combination of recombinant interferon alpha-2a (18 times 10(6) units subcutaneously 3 times weekly) and vinblastine (0.1 mg. per kg. intravenously every 3 weeks). Four patients were ineligible and 6 were inevaluable for response but evaluable for toxicity. There were no complete and 9 partial responses among the 56 evaluable patients, for a response rate of 16 per cent. Median duration of response was 26 weeks, with a range of 8 to 50 weeks. Responses were observed predominantly in patients with lung and soft tissue metastases. Patients who had undergone nephrectomy did not show a better response rate than those who had not. Almost all patients had a flu-like syndrome, fatigue and anorexia. Other side effects included leukopenia, nausea, vomiting, liver function disturbances and neurotoxicity. Most of the side effects were World Health Organization grade 1 or 2; no grade 4 toxicity was observed. Antibodies against interferon developed in 6 patients during the course of treatment. However, there was no relationship between the appearance of antibodies and disease progression. The combination of recombinant interferon alpha-2a and vinblastine has modest but definite activity in patients with advanced renal cell carcinoma, although the role of vinblastine is unclear.
15
Reporting results of cancer treatment
A. B. Miller, Barth Hoogstraten, M. Staquet et al. · Cancer · 1981 · 7.9K citations
Renal cell carcinoma: antitumor effects of leukocyte interferon.
Jorge R. Quesada, David A. Swanson, Antonio Trindade et al. · PubMed · 1983 · 316 citations
Medicine, Oncology, Pharmacology +17
The Treatment of Renal Cell Carcinoma with Human Leukocyte Alpha-Interferon
Jean B. deKernion, Gregory Sarna, Robert A. Figlin et al. · The Journal of Urology · 1983 · 174 citations
Medicine, Immunology, Oncology +12